Ireland inhalers market is expected to grow at steady rate an
impressive rate during the forecast period on account of rising prevalence
of chronic respiratory diseases (CRDs) across the country, increase in air
pollution, rise in number of asthma patients, increase in number of clinical
trials for better clinical and therapeutics for asthma is expected to drive the
growth of Ireland inhalers market during the forecast period. For instance,
according to Center for Disease Control and Prevention (CDC), during the
coronavirus pandemic individuals suffering from moderate to severe asthma were
at a greater risk of falling ill with acute respiratory disease. Furthermore,
rising healthcare expenditure and rise in research and development expected to
bolster the growth of the Ireland inhalers market. These factors are actively
driving the growth of the Ireland inhalers market in the upcoming five years,
2024-2028.
Asthma is a major non-communicable
disease that affects both adults and childrens. The chronic obstructive
pulmonary disease (COPD) was responsible for about 3.23 million deaths in the
same year.
One of the key drivers of growth is
increasing focus on the development of inhalers and a rise in initiatives by
key market players for research and development, which are driving the demand
for Ireland inhalers market.
One of the key drivers of growth in the Ireland
inhalers market is rise in geriatric population. The National Institute of
Health estimates that among adults in Ireland, the prevalence of the four major
chronic disease categories is 5.2% for diabetes, 9.4% for cardiovascular
disease (CVD), and 9.8% for chronic obstructive pulmonary disease (COPD).
Another factor driving growth in the Ireland inhalers market is the rising
interest of different market players for new product launches and new
technology. In Ireland, there are 6,300 persons with severe asthma, or about
470,000 people overall, according to the National Institute of Health.
According to the European Community Respiratory Health Survey (ECRHS), among
patients aged 20 to 44 in Europe, Ireland had the highest prevalence of severe
asthma attacks (6%) over the previous 12 months. In fact, the government
has prioritized healthcare and devoted a sizable number of resources to
enhancing healthcare spending and services. Due to the favorable atmosphere,
this has produced, there is an increasing need to construct new prospects.
Furthermore, the ongoing research and
development of technology in the development of therapy for asthma treatment using
inhalers is expected to aid the growth of the Ireland inhalers market in the
forecast period, 2024-2028. Moreover, the government also supports the idea by
increasing investment in the pharmaceutical sector and the pharmaceutical
companies to enforce manufacturers for taking interest in research and
development of advanced treatment in Ireland to bolster the growth of Ireland inhalers
market.
Rising Prevalence of Chronic Diseases
Asthma is the most common chronic
disease. For instance, according to WHO, asthma affected about 262 million
people and 455,000 people succumbed to the disease in 2019. Majority of asthma
related deaths occur in low and lower middle-income countries where
underdiagnosis and undertreatment are common. Asthma can be a persisting
and recurring health problem, thus increasing the likelihood of health, social,
and economic costs for the individuals, their families and on the healthcare
system across the country. We can prevent from asthma by proceeding with
reduced tobacco, affordable medication, long term illness scheme, DPS threshold
reduction, clean outdoor air, clear outdoor air in the home. According to
Asthma society of Ireland, in 2019, 890,000 people experience asthma at some
stage of their life in which 380,000 people in Ireland currently have asthma.
.
Increasing Prevalence of Respiratory
Diseases
The rising prevalence of respiratory
conditions, such as asthma, COPD, and other chronic lung diseases, is a
significant driver of Ireland Inhalers treatment market. This is ascribed due
to air pollution, smoking, and genetic predisposition contribute to the high
incidence of these diseases. As the number of individuals diagnosed with
respiratory conditions increases, the demand for inhaler treatments also rises.
According to Irish Thoracic Society, respiratory disease led to 5,720 deaths
and 14.3% of all inpatient hospitalizations in Ireland in 2016. Respiratory
disease causes almost one in 5 deaths in Ireland. Lung cancer accounted for
1,864 deaths (20.6% of cancer deaths) in Ireland in 2016. This was an increase
of 11.8% (1,668) on the 2007 figure. Additionally, respiratory diseases can
significantly impact the quality of life for individuals, causing symptoms such
as wheezing, coughing, shortness of breath, and chest tightness. Inhalers
provide quick relief from these symptoms and help manage the underlying
condition. With a higher prevalence of respiratory diseases, the need for
inhaler treatments becomes crucial to alleviate symptoms, prevent
exacerbations, and improve overall respiratory health. According to Irish
Thoracic Society, Ireland has the highest hospitalization rate for COPD
(Chronic Obstructive Pulmonary Disease) among selected OECD countries with over
87% of these admitted as emergencies. Hence, these factors are responsible
for driving the growth of Ireland inhalers market.
Advancements in Research and Development
The ongoing research and development
efforts in the field of respiratory medicine have led to the introduction of
new and improved inhaler therapies. The pharmaceutical companies invest in
developing novel medications, combination therapies, and targeted treatments to
address specific respiratory conditions. These advancements provide healthcare
professionals with more treatment options, further driving the growth of Ireland
inhalers treatment market. According to clinicaltrials.gov, 1685 studies are
found for inhalers which provides a biggest support in the treatment of asthma
and Chronic Obstructive Pulmonary Disease (COPD). Due to this research in
healthcare digital inhaler, health
platforms are developed, which incorporate digital inhalers to monitor time and
date of dosing. These are an effective disease and medication management tool,
promoting collaborative care between clinicians and patients, and providing
more in-depth understanding of actual inhaler use. Thereby, propelling the
growth of Ireland inhalers market.
Increasing Air Pollution Triggering Asthma
Cases
Inhalers are used in Asthma to get
relief instantly. Asthma is a chronic respiratory condition marked by
fluctuating airflow restriction, bronchial hyper responsiveness, and
inflammation of the airways. Air pollution appears to have a negative impact on
asthma outcomes in both adults and children. For instance, according to
research, the air pollution from traffic, nitrogen dioxide, and second-hand
smoking (SHS) are all substantial risk factors for the development of asthma in
children. Asthma symptoms, exacerbations, and decreased lung function can
all be triggered by exposure to outside pollution as the outside environment is
very polluted and is expected to bolster the growth of Ireland inhalers market.
Download Free Sample Report
Market Segmentation
The Ireland inhalers market is segmented
by product, technology, disease indication, regional distribution, and
competitional landscape. Based on product, the market is further bifurcated
into dry powder inhalers, metered dose
inhalers, and nebulizers. Based on technology, the market is bifurcated
into manual operated inhaler devices and digitally operated inhaler devices.
Based on disease indication, the market is bifurcated into asthma, chronic obstructive pulmonary
diseases, pulmonary arterial hypertension, and others.
Market Players
GlaxoSmithKline Ireland, AstraZeneca
Ireland Limited, Propeller Health, Teva Pharmaceuticals Ireland Limited, and Novartis
Ireland Limited are some of the leading companies operating in the Ireland inhalers
market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historical Years
|
2018 – 2022
|
|
Estimated Year
|
2022E
|
|
Forecast Period
|
2023F – 2028F
|
|
Quantitative Units
|
Revenue in USD Million, Volume in Units, and CAGR for
2017-2021 and 2022E-2028F
|
|
Report Coverage
|
Revenue forecast, volume forecast, company share, competitive
landscape, growth factors, and trends
|
|
Segments Covered
|
Product
Technology
Disease Indication
Region
Company
|
|
Region Scope
|
Northern Ireland, North-West, West, Midland East, Dublin,
Shannon, South-East, Cork-Kerry
|
|
Key Companies Profiled
|
GlaxoSmithKline Ireland, AstraZeneca Ireland Limited,
Propeller Health, Teva Pharmaceuticals Ireland Limited, Novartis Ireland
Limited
|
|
Customization Scope
|
10% free report customization with purchase. Addition or
alteration to regional & segment scope.
|
|
Pricing and Purchase Options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery Format
|
PDF
and Excel through Email (We can also provide the editable version of the
report in PPT/Word format on special request)
|
Report Scope:
In this report, Ireland inhalers market has been segmented
into following categories, in addition to the industry trends which have also
been detailed below:
- Ireland Inhalers
Market, By Product:
o
Dry
Powder Inhalers
o
Metered
Dose Inhalers, Nebulizers
- Ireland Inhalers
Market, By Technology:
- Manual Operated Inhaler Devices
- Digitally Operated Inhaler Devices
- Ireland Inhalers
Market, By Disease Indication:
- Asthma
- Chronic
Obstructive Pulmonary Diseases
- Pulmonary
Arterial Hypertension
- Others
- Ireland Inhalers
Market, By Region:
- Northern Ireland
- North-West
- West
- Midland East
- Dublin
- Shannon
- South-East
- Cork-Kerry
Competitive Landscape
Company Profiles: Detailed analysis of the major
companies present in Ireland inhalers market.
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following
customization options are available for the report:
Company Information
Detailed analysis and
profiling of additional market players (up to five)